Dossiers d'AMM à étudier par le Comité Technique des Spécialités Pharmaceutiques du 07/09/2023.
Pour ce comité technique, l’ordre de passage des dossiers sera comme suit .
Spécialités Pharmaceutiques importées
* Produits déjà évalués lors des derniers Comités Techniques
N° | Médicament | DCI | Dosage | Forme Pharmaceutique | Présentation | TITULAIRE | VEIC | Type de demande | date du courrier |
1 | PROXIDA | Dexmedetomidine | 200 µG/2ml | SOL INJ PR PERF | B/1FL | HIKMA Pharmaceuticals | N | 02/03/2023 | |
2 | ISOSUPRA LIDOSE | ISOTRETINOINE | 8 Mg | Gélule | B/30 | SMB SA | I | N | 03/07/2023 |
3 | TARKA | TRANDOLAPRIL+VERAPAMIL | 180mg /2 mg | COMP LP | B/28 | ABBOTT GmbH & Co.KG | E | N | 03/07/2023 |
4 | TARKA FORTE | TRANDOLAPRIL+VERAPAMIL | 240 mg /4 mg | COMP LP | B/28 | ABBOTT GmbH & Co.KG | E | N | 03/07/2023 |
5 | XELJANZ XR | TOFACITINIB | 11 mg | COMP PEL LP | B/30 | Pfizer Inc USA | E | N | 05/08/2023 |
6 | SIMULECT | BASILIXIMAB | 20 mg | PDRE PR PREP INJ | B/1FL+S/5 ml | NOVARTIS PHARMA SCHWEIZ AG | V | T | 05/10/2023 |
7 | DEXMEDETOMIDINE EVER PHARMA | Dexmedetomidine | 1000µg/10ml (100µg/ml) | SOL INJ PR PERF | B/5FL/10ML | EVER Valinject GmbH | N | 24/05/2023 | |
8 | DEXMEDETOMIDINE EVER PHARMA | Dexmedetomidine | 400µg/4ml (100µg/ml) | SOL INJ PR PERF | B/5FL/5ML | EVER Valinject GmbH | N | 24/05/2023 | |
9 | DEXMEDETOMIDINE EVER PHARMA | Dexmedetomidine | 200µg/2ml (100µg/ml) | SOL INJ PR PERF | B/5FL/2ML | EVER Valinject GmbH | N | 24/05/2023 | |
10 | VESSEL | SULODEXIDE | 600 UL | SOL IN | B/10 | ALFASIGMA | I | V | 23/06/2023 |
11 | VESSEL | SULODEXIDE | 250 UL | CAPSULE MOLLE | B/50 | ALFASIGMA | I | V | 23/06/2023 |
12 | MYCOTEN | CLOTRIMAZOLE | 200 mg | COMP GYN | B/3 avec applicateurs | BEIT JALA Pharmaceutical Co | I | N | 07/05/2023 |
13 | MYCOTEN | CLOTRIMAZOLE | 500 mg | COMP VAGINAL | B/1 Comprimé + Applicateur | BEIT JALA Pharmaceutical Co | I | N | 07/05/2023 |
14 | MYCOTEN VAGINAL CREAM | CLOTRIMAZOLE | 2% | CREME VAGINAL | T/20g | BEIT JALA Pharmaceutical Co | I | N | 07/05/2023 |
15 | HEALER CREME | MAFENIDE ACETATE | 8.5% | CREME DERMIQUE | T/15 gr | BEIT JALA Pharmaceutical Co | C | N | 45112 |
16 | SKYRIZI | RISANKIZUMAB | 75 mg | SOL INJ | B/2SERINGUE | ABBVIE DEUTSCHLAND Gmbh and Co.KG | N | 14/07/2023 | |
17 | DUOPLAVIN | CLOPIDOGREL+ ACIDE ACETYLSALICYLIQUE | 75 mg/100 mg | COMP PEL LP | B/28 | SANOFI PHARMA B.M.S SNC | N | 08/11/2023 | |
18 | RILUZOL PMCS | RILUZOLE | 50 mg | COMP PEL | B/56 | PRO.MED.CS Praha a.s | N | 30/08/2023 | |
19 | JARDIANCE | EMBAGLIFLOZINE | 25 mg | COMP PEL | B/30 | BOEHRINGER INGELHEIM | E | V | 09/04/2023 |
20 | JARDIANCE | EMBAGLIFLOZINE | 10 mg | COMP PEL | B/30 | BOEHRINGER INGELHEIM | E | V | 09/04/2023 |
* Produits à évaluer pour la première fois au Comité Technique
N° | Médicament | DCI | Dosage | Forme Pharmaceutique | Présentation | TITULAIRE | VEIC | Type de la demande | DATE RE |
1 | COSENTYX SensoReady | SECUKINUMAB | 150 MG/ML | SOL INJ | B/2 Stylos pré_remplis | NOVARTIS PHARMA SCHWEIZ AG | E | T | 14/06/2023 |
2 | BEOVU | BROLUCIZUMAB | 120 MG/ML | SOL INJ | B/1 SER | NOVARTIS EUROPHARM LIMITED IRLANDE | N | 14/06/2023 | |
3 | TREMFYA | GUSELKUMAB | 100 mg | SOL INJ | B/1 stylo pré-rempli | Janssen-Cilag International N.V | E | N | 14/06/2023 |
4 | TREMFYA | GUSELKUMAB | 100 mg | SOL INJ | B/1 SER pré-remplie | Janssen-Cilag International N.V | E | N | 14/06/2023 |
5 | Skyrizi | Risankizumab | 150 mg | SERINGUE pré-rempli | B/1 | Abbvie -NL | E | N | 14/06/2023 |
6 | Skyrizi | Risankizumab | 150 mg | STYLO pré-rempli | B/1 | Abbvie -NL | E | N | 14/06/2023 |
7 | Humira | ADALIMUMAB | 40 MG | SERINGUE pré-rempli | B/2 | ABBVIE DEUTSCHLAND GmbH & Co,KG | E | V | 14/06/2023 |
8 | CARBAGLU | ACIDE CARGLUMIQUE | 200 MG | COMP DISPERSIBLE | B/5 | RECORDATI RARE DISEASES | N | 21/06/2023 | |
9 | CARBAGLU | ACIDE CARGLUMIQUE | 200 MG | COMP DISPERSIBLE | B/60 | RECORDATI RARE DISEASES | N | 21/06/2023 | |
10 | BRUKINSA | ZANUBRUTINIB | 80 MG | GELULLE | FL/120 | BeiGene USA,Inc | N | 21/06/2023 | |
11 | DARZALEX | daratumumab | 1800 MG | SOL INJ | B/1FL/15ML | Janssen-Cilag International N.V | N | 21/06/2023 | |
12 | ULTRA - LEVURE | SACCHAROMYCES BOULARDII CNCM I-745 | 200 mg | GELULLE | B/10 | BIOCODEX | E | N | 21/06/2023 |
13 | IMATINIB MYLAN | IMATINIB | 400 mg | COMP PEL | B/30 | MYLAN S.A.S | V | N | 21/06/2023 |
14 | IMATINIB MYLAN | IMATINIB | 100 mg | COMP PEL | B/60 | MYLAN S.A.S | V | N | 21/06/2023 |
15 | KESIMPTA | OFATUMUMAB | 20 mg/0.4ml | SOL INJ | B/1 stylo | NOVARTIS PHARMA SCHWEIZ AG | N | 21/06/2023 | |
16 | DARZALEX | DANATUMUMAB | 20 MG/ML | SOL PR PRF | B/1FL/5ML | JANSSEN CILAG INT N,V | V | 21/06/2023 | |
17 | DARZALEX | DANATUMUMAB | 20 MG/ML | SOL PR PRF | B/1FL/20ML | JANSSEN CILAG INT N,V | V | 21/06/2023 | |
18 | FOLICUM | ACIDE FOLIQUE | 5 MG | COMP | B/20 | JULPHAR | E | V | 13/07/2023 |
19 | EVRYSDI | RISDIPLAM | 0.75 mg/ml | PDRE PR SOL ORAL | FL/100 ml | Roche Pharma (Schweiz) AG | N | 15/08/2023 | |
20 | CRESEMBA | ISAVUCONAZOLE | 100 MG | GELULLE | B/14 | HIKMA Pharmaceuticals | N | 15/08/2023 | |
21 | DICYNONE | ETAMSYLATE | 250 MG/2ML | SOL INJ | B/6/2ML | OMEDICAMED UNIPESSOAL LDA | C | T | 29/08/2023 |
22 | DICYNONE | ETAMSYLATE | 250 mg | COMP | B/20 | OMEDICAMED UNIPESSOAL LDA | C | T | 29/08/2023 |